Form 4: Karyopharm CEO Paulson Awarded 81,060 RSUs

Karyopharm Therapeutics Inc. CEO Richard Paulson received an award of 81,060 restricted stock units vesting over two years.

Summary

• Richard A. Paulson, President and CEO, and a Director of Karyopharm Therapeutics Inc. (KPTI), was awarded 81,060 restricted stock units (RSUs).
• The RSUs were granted on February 5, 2026, under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended.
• These RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
• The vesting schedule for these RSUs is 50% of the shares on January 31, 2027, and the remaining 50% on January 31, 2028.
• Following this award, Richard A. Paulson beneficially owns 279,391 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development for corporate governance and management alignment, as it ties executive compensation directly to future stock performance, encouraging long-term value creation.

Positives

• The award of restricted stock units aligns the CEO's long-term incentives with shareholder value, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule encourages executive retention over a multi-year period.

Future Outlook

The RSU award with a multi-year vesting schedule indicates a commitment to retaining key leadership and aligning their interests with the company's long-term performance and growth, as the value of the award is contingent on future stock price appreciation.

Industry Context

StockSavvy.ai notes that the award of restricted stock units is a standard and widely adopted practice in executive compensation across the biotechnology and pharmaceutical industries. This method is favored for its ability to align the interests of executives with those of shareholders by tying a significant portion of compensation to the company's future stock performance and long-term value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a common practice among publicly traded biotechnology and pharmaceutical companies, similar to peers like Amgen Inc. (AMGN) or Gilead Sciences, Inc. (GILD), which frequently utilize equity awards to incentivize and retain top management.
• The vesting schedule, typically over several years, is also standard, aiming to foster long-term commitment and performance, consistent with industry benchmarks for executive incentive plans.

Corporate Governance

Related Party Transactions

• Award of 81,060 restricted stock units to Richard A. Paulson, President and CEO, and Director, under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term stock performance.
• Employees: No direct impact mentioned, but reflects ongoing executive compensation practices.
• Management: Positive impact through equity compensation, incentivizing long-term commitment and performance.

Next Steps

• The awarded RSUs will vest in two tranches: 50% on January 31, 2027, and the remaining 50% on January 31, 2028.

Key Dates

Recommendation

The RSU award to the CEO is a standard executive compensation practice designed to align management incentives with long-term shareholder value. It does not present new information that would significantly alter the investment thesis for Karyopharm Therapeutics Inc. at this time, thus a 'hold' recommendation is appropriate.

Keywords

Karyopharm Therapeutics, KPTI, Richard Paulson, Restricted Stock Units, RSU Award, Executive Compensation, Insider Transaction, Equity Incentive Plan, Biotechnology, Pharmaceuticals